Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases
Authors:
Open Access
- 17 June 2025
- journal article
- review article
- Published by Elsevier in Materials Today Bio
- Vol. 33, 101992
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82202135)
- China Postdoctoral Science Foundation (2023M741808)
This publication has 181 references indexed in Scilit:
- Engineered Macrophage Membrane‐Coated S100A9‐siRNA for Ameliorating Myocardial Ischemia‐Reperfusion InjuryAdvanced Science, 2024
- Hybrid Membrane‐Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's DiseaseAdvanced Science, 2024
- Beyond Extracellular Vesicles: Hybrid Membrane Nanovesicles as Emerging Advanced Tools for Biomedical ApplicationsAdvanced Science, 2023
- Functionalized Macrophage Exosomes with Panobinostat and PPM1D‐siRNA for Diffuse Intrinsic Pontine Gliomas TherapyAdvanced Science, 2022
- Platelet‐Like Fusogenic Liposome‐Mediated Targeting Delivery of miR‐21 Improves Myocardial Remodeling by Reprogramming Macrophages Post Myocardial Ischemia‐Reperfusion InjuryAdvanced Science, 2021
- Cell Membrane Coating NanotechnologyAdvanced Materials, 2018
- Neutrophil‐Based Drug Delivery SystemsAdvanced Materials, 2018
- In Situ Capture of Bacterial Toxins for Antivirulence VaccinationAdvanced Materials, 2017
- Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle FunctionalizationAdvanced Materials, 2017
- Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and ThrombusAdvanced Materials, 2016